Syndax Pharmaceuticals (Nasdaq:SNDX) granted inducement stock options to eight new employees on July 1, 2026 under its 2023 Inducement Plan. The awards cover up to 250,700 shares of common stock and vest over four years, subject to continued employment-based service conditions.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SNDX
+4.45%
1 alert
+4.45%Session close to close
$1.93BMarket Cap
11.32KVolume
In the Jul 2 session, SNDX gained 4.45%, reflecting a moderate positive market reaction.
This announcement details 250,700 inducement stock options for 8 new hires, vesting over 4 years. It...
Analysis
This announcement details 250,700 inducement stock options for 8 new hires, vesting over 4 years. It follows recent clinical, financing and insider activity; investors may watch how added equity awards interact with already elevated short interest.
Key Figures
Inducement options granted:250,700 sharesNew employees:8 employeesVesting period:4 years+3 more
6 metrics
Inducement options granted250,700 sharesStock options to eight new employees under 2023 Inducement Plan
New employees8 employeesRecipients of inducement stock option awards
Vesting period4 yearsTotal vesting period for inducement stock options
Cliff vesting25% of sharesVest on first anniversary of vesting commencement date
Monthly vesting fraction1/48th of sharesMonthly vesting after first anniversary over remaining term
Post-cliff vesting duration36 monthsMonthly vesting schedule following initial one-year cliff
"Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement planfinancial
"under the Company's 2023 Inducement Plan."
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
stock optionsfinancial
"The stock options will vest over four years, with 25% of the underlying"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vesting commencement datefinancial
"on the one-year anniversary of the vesting commencement date and 1/48th"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2026, the Company granted inducement awards to purchase up to 250,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre Syndax Pharmaceuticals, Inc. sklahre@syndax.com Tel 781.684.9827
FAQ
What inducement grants did Syndax Pharmaceuticals (SNDX) announce on July 1, 2026?
Syndax Pharmaceuticals announced stock option inducement awards covering up to 250,700 shares for eight new employees. According to the company, these options were granted under its 2023 Inducement Plan as a material component of the employees’ compensation and hiring incentives.
How many shares are included in the new Syndax Pharmaceuticals (SNDX) inducement stock options?
The inducement stock options cover up to 250,700 shares of Syndax common stock. According to the company, these awards were granted to eight newly hired employees as part of their equity compensation package under the 2023 Inducement Plan.
What is the vesting schedule for the new Syndax (SNDX) inducement stock options granted in July 2026?
The Syndax inducement options vest over four years. According to the company, 25% vests on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the following 36 months.
Who received the July 1, 2026 inducement stock option awards from Syndax Pharmaceuticals (SNDX)?
Eight new employees received the inducement stock option awards from Syndax Pharmaceuticals. According to the company, these grants are tied to the employees’ continued service, aligning long-term incentives with the company’s commercial-stage biopharmaceutical objectives in advancing cancer therapies.
Under which equity plan were the July 2026 Syndax (SNDX) inducement awards granted?
The July 2026 inducement awards were granted under Syndax’s 2023 Inducement Plan. According to the company, this plan is specifically used for equity grants to new employees as inducements to join the organization, separate from its existing shareholder-approved plans.
What employment condition applies to the vesting of Syndax Pharmaceuticals’ (SNDX) July 2026 inducement options?
Vesting of the July 2026 inducement options requires continued service with Syndax. According to the company, employees must maintain their service relationship through each applicable vesting date for both the initial one-year cliff vest and subsequent monthly vesting installments.
